MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion

1. MedinCell, a French company, and AbbVie have entered into a partnership for the development of long-acting injectable therapies.
2. The collaboration is valued at up to $1.9 billion.
3. MedinCell has a history of developing slow-release injectable drug technology for over 20 years.
4. MedinCell, in collaboration with Teva, recently received FDA approval for Uzedy (risperidone), an extended-release injectable suspension for adults with schizophrenia.
5. Uzedy can be administered at one- or two-month intervals, with therapeutic blood concentrations reached in 6 to 24 hours after dosing.
6. Uzedy's approval is supported by two Phase 3 trials, RISE and SHINE, which demonstrated reduced relapse risk compared to placebo.
7. MedinCell's BEPO technology (SteadyTeq) is based on copolymers and a biocompatible solvent formulated with the active ingredient, providing a gradual drug release.
8. The long-acting schizophrenia drug market is competitive, with products like Otsuka and Lundbeck's Abilify Asimtufii and J&J's Invega Sustenna and Invega Trinza.
9. The partnership between MedinCell and AbbVie aims to develop innovative long-acting injectable therapies.